Founded Year



Seed VC | Alive

Mosaic Score

+40 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Mindbloom

Mindbloom provides a platform that helps licensed psychiatric clinicians to achieve better outcomes for their patients with lower costs and greater convenience. The company provides science-backed mental health research and provides health and well-being treatments specifically through ketamine therapy for depression and anxiety.

Mindbloom Headquarters Location

99 Wall Street #1561

New York, New York, 10005,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Mindbloom's Products & Differentiation

See Mindbloom's products and how their products differentiate from alternatives and competitors

  • Mindbloom

    We alchemize prescription ketamine, software, content, a physical kit, and human care from psychiatric clinicians and psychedelic guides into personalized, at-home experiences





    clinical and coaching services 


Research containing Mindbloom

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Mindbloom in 4 CB Insights research briefs, most recently on Dec 8, 2021.

Expert Collections containing Mindbloom

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mindbloom is included in 5 Expert Collections, including Mental Health Tech.


Mental Health Tech

1,230 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.



247 items


Digital Health 150

150 items

The winners of the second annual CB Insights Digital Health 150.


Digital Health

13,099 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)



2,842 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Latest Mindbloom News

08:00 EDT Largest-ever clinical study of ketamine therapy shows that at-home model can be a safe, effective treatment for anxiet...

Jul 18, 2022

News provided by Share this article Share this article AUSTIN, Texas, July 18, 2022 /PRNewswire/ -- Mindbloom , the leading provider of at-home ketamine therapy, announced Monday the findings of the largest-ever peer-reviewed clinical study of ketamine therapy. Authored by psychiatrists and researchers from MAPS , the Cleveland Clinic, UCSF, NYU and Houston Methodist, the study, which has been accepted into the Journal of Affective Disorders to be published in its October edition, shows that at-home sublingual ketamine therapy can be a safe, effective treatment for anxiety and depression. In the largest-ever study of ketamine therapy, Mindbloom's at-home ketamine therapy outperformed outcomes in studies of antidepressant SSRI's and psychotherapy. Mindbloom's at-home ketamine therapy is available for patients presenting with symptoms of depression and anxiety. Across a cohort of 1,247 patients, 89% of participants presenting with anxiety and/or depression showed an improvement in their symptoms after just four sessions. In total, 63% of participants saw a greater than 50% improvement in their symptoms. These results are 34% stronger1 than what has been observed in studies of traditional antidepressants (such as SSRIs) and 54% stronger than results shown in studies of psychotherapy.2 Outcomes were also shown to be 17% stronger than those observed in studies of ketamine infusion treatments, despite Mindbloom's sublingual ketamine treatments being cheaper and less invasive. "This landmark study showed outcomes for at-home ketamine therapy that far exceeded those of traditional depression treatments," said Mindbloom Medical Director Dr. Leonardo Vando. "This therapy compares very favorably against studies on traditional treatments like SSRI antidepressants and talk therapy. We believe that the support provided by our clinicians and guides and the comfort of our at-home, needle-free administration method contribute to the therapy's effectiveness." The study also found that 62% of patients presenting with suicidal ideation prior to treatment no longer reported any suicidal ideation after four sessions. Side effects were also shown to be rare. Fewer than 5% of patients reported any side effects, and of the 1,247 patients in the study, only four dropped out of treatment due to adverse events. "The results of this study make it clear that ketamine therapy is the future of mental healthcare," said Mindbloom Founder & CEO Dylan Beynon. "This groundbreaking study is an opportunity to dispel common misconceptions about ketamine therapy, and to help us bring its healing power to more people than ever before." Mindbloom is the leader in ketamine therapy, offering a combination of science-backed medicine with clinician and guide support for people looking to improve their mental health and wellbeing. Founded by three-time entrepreneur Dylan Beynon, Mindbloom aims to address the mental health crisis through at-home ketamine therapy. This at-home approach increases access to an affordable, safe and effective emerging treatment option. For more information, visit .

Mindbloom Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Mindbloom Rank

  • When was Mindbloom founded?

    Mindbloom was founded in 2019.

  • Where is Mindbloom's headquarters?

    Mindbloom's headquarters is located at 99 Wall Street, New York.

  • What is Mindbloom's latest funding round?

    Mindbloom's latest funding round is Seed VC.

  • Who are the investors of Mindbloom?

    Investors of Mindbloom include Founders Fund.

  • Who are Mindbloom's competitors?

    Competitors of Mindbloom include NUE Life Health and 3 more.

  • What products does Mindbloom offer?

    Mindbloom's products include Mindbloom.

You May Also Like

NUE Life Health Logo
NUE Life Health

NUE Life Health is a telemedicine startup that develops a mental wellness solution employing treatments such as psychedelic-assisted therapies, combined with a graph database-driven app. NUE Life Health was founded in 2020 and is based in Miami Beach, Florida.


Journey offers ketamine-assisted psychotherapy and integration services.

Clairvoyant Therapeutics

Clairvoyant Therapeutics is a biotechnology company focused on short path clinical trial speed to market strategy for psilocybin psycho-assisted therapy. The company was founded in 2021 and is based in Vancouver Canada.

Compass Pathways Logo
Compass Pathways

Compass Pathways (NASDAQ: CMPS) develops psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression.

MindMed Logo

Mindmed discovers, develops, and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.

Field Trip Health & Wellness

Field Trip Health & Wellness (TSX: FTHW) provides mental health clinics that offer mental wellness, mental health research, drug discovery, psychedelics, holistic health, and therapeutic psychedelics. It uses a spectrum approach to backing psychedelic research. It invests in psychedelic startups and operating and managing companies in the space. The company was formerly known as Field Trip Health and rebranded into Field Trip Health & Wellness. The company was founded in 2019 and is based in Toronto, Canada.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.